Literature DB >> 3311119

Inhaled ceftazidime compared with gentamicin and carbenicillin in older patients with cystic fibrosis infected with Pseudomonas aeruginosa.

R J Stead1, M E Hodson, J C Batten.   

Abstract

A randomized cross-over study was undertaken to compare nebulized (1) ceftazidime with (2) a combination of gentamicin and carbenicillin, and (3) saline, each given for 4 months, in patients with cystic fibrosis infected with Pseudomonas aeruginosa. Mean peak expiratory flow on ceftazidime, 299 litres/min, and on gentamicin and carbenicillin, 297 litres/min, were greater than on saline, 278 litres/min (P less than 0.02 and P less than 0.05 respectively). Similarly mean forced expiratory volume in 1 second on ceftazidime, 1.70 litres, and on gentamicin and carbenicillin, 1.70 litres, were greater than on saline, 1.48 litres (P less than 0.02 and P less than 0.01 respectively). Mean forced vital capacity on gentamicin and carbenicillin, 2.93 litres, was also greater than on saline (P less than 0.05). We were unable to demonstrate any difference in efficacy between the antibiotic regimens. The patients were admitted to hospital less frequently during the study year compared with the previous year (P less than 0.05). Sixty-nine per cent of patients had a clinically significant (20%) increase in forced expiratory volume in 1 second on an antibiotic regimen compared with that on entry to study, but a minority of patients appear not to respond to this form of treatment.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3311119     DOI: 10.1016/0007-0971(87)90161-6

Source DB:  PubMed          Journal:  Br J Dis Chest        ISSN: 0007-0971


  13 in total

1.  Is prolonged rotavirus infection a common cause of protracted diarrhoea?

Authors:  M Sood; I W Booth
Journal:  Arch Dis Child       Date:  1999-04       Impact factor: 3.791

2.  Evidence for using nebulised antibiotics in cystic fibrosis.

Authors:  S P Conway
Journal:  Arch Dis Child       Date:  1999-04       Impact factor: 3.791

Review 3.  Lung infections. 3. Pseudomonas aeruginosa and other related species.

Authors:  R Wilson; R B Dowling
Journal:  Thorax       Date:  1998-03       Impact factor: 9.139

Review 4.  Aerosol antibiotic treatment in cystic fibrosis.

Authors:  J M Littlewood; S W Smye; H Cunliffe
Journal:  Arch Dis Child       Date:  1993-06       Impact factor: 3.791

5.  Pharmacokinetics of aerosolized tobramycin in adult patients with cystic fibrosis.

Authors:  D J Touw; F A Jacobs; R W Brimicombe; H G Heijerman; W Bakker; D D Briemer
Journal:  Antimicrob Agents Chemother       Date:  1997-01       Impact factor: 5.191

Review 6.  Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis.

Authors:  Sherie Smith; Nicola J Rowbotham; Edward Charbek
Journal:  Cochrane Database Syst Rev       Date:  2022-08-01

7.  Urinary N-acetyl-beta-D-glucosaminidase activity in patients with cystic fibrosis on long-term gentamicin inhalation.

Authors:  E Ring; E Eber; W Erwa; M S Zach
Journal:  Arch Dis Child       Date:  1998-06       Impact factor: 3.791

8.  Protection by antibiotics against myeloperoxidase-dependent cytotoxicity to lung epithelial cells in vitro.

Authors:  A Cantin; D E Woods
Journal:  J Clin Invest       Date:  1993-01       Impact factor: 14.808

Review 9.  Nebulized antibiotics in cystic fibrosis.

Authors:  Isabelle Sermet-Gaudelus; Yann Le Cocguic; Agnés Ferroni; Marlène Clairicia; Joel Barthe; Jan-Pierre Delaunay; Valentine Brousse; Gérard Lenoir
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

10.  Tobramycin administered by the TOBI(®) Podhaler(®) for persons with cystic fibrosis: a review.

Authors:  Donald R Vandevanter; David E Geller
Journal:  Med Devices (Auckl)       Date:  2011-09-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.